Benzene Ring Nonionically Bonded Patents (Class 514/567)
-
Patent number: 9622996Abstract: A method for treating an cancer disease is disclosed comprising administering to a subject a pharmaceutical composition comprising an adrenergic beta-3-receptor blocker.Type: GrantFiled: January 30, 2013Date of Patent: April 18, 2017Inventors: Shuguang Lin, Meng Zheng
-
Patent number: 9610269Abstract: The present invention discloses a method of treating a disease condition susceptible to baclofen therapy, said method comprising orally administering once-a-day in the evening a controlled release drug delivery system comprising baclofen or its pharmaceutically acceptable salt or its derivatives and pharmaceutically acceptable excipients.Type: GrantFiled: December 16, 2013Date of Patent: April 4, 2017Assignee: SUN PHARMA ADVANCED RESEARCH COMPANY LTD.Inventors: Nitin Bhalachandra Dharmadhikari, Yashoraj Rupsinh Zala
-
Patent number: 9579385Abstract: Compositions and methods related to ophthalmic use of polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymers and therapeutic uses are described herein.Type: GrantFiled: January 10, 2014Date of Patent: February 28, 2017Assignee: ALLERGAN, INC.Inventors: Anuradha V. Gore, Chetan P. Pujara, Richard S. Graham, Melissa Gulmezian, Kristin Prinn, Ramakrishnan Srikumar
-
Patent number: 9561277Abstract: An aqueous liquid preparation of the present invention containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or a hydrate thereof, an alkyl aryl polyether alcohol type polymer such as tyloxapol, or a polyethylene glycol fatty acid ester such as polyethylene glycol monostearate is stable. Since even in the case where a preservative is incorporated into said aqueous liquid preparation, the preservative exhibits a sufficient preservative effect for a long time, said aqueous liquid preparation in the form of an eye drop is useful for the treatment of blepharitis, conjunctivitis, scleritis, and postoperative inflammation. Also, the aqueous liquid preparation of the present invention in the form of a nasal drop is useful for the treatment of allergic rhinitis and inflammatory rhinitis (e.g. chronic rhinitis, hypertrophic rhinitis, nasal polyp, etc.).Type: GrantFiled: September 30, 2014Date of Patent: February 7, 2017Assignee: SENJU PHARMACEUTICAL CO., LTD.Inventors: Shirou Sawa, Shuhei Fujita
-
Patent number: 9555025Abstract: Provided is an ointment which has excellent drug stability and excellent drug uniformity. The ointment, which comprises 1 to 5% by weight of 1-[2-[(4S)-4-hydroxy-1,2,3,4-tetrahydroquinolin-1-yl]-4-pyridyl]-2,3-bis(hydroxymethyl)-6,7-dimethoxynaphthalene·3/2 hydrate, 3 to 7% by weight of a separation inhibitor, 15 to 50% by weight of a hydrocarbon gel, a pH controller and 0.05 to 0.4% by weight of an antioxidant, has excellent drug stability and excellent drug dispersibility. In the present ointment, polyoxyethylene (196) polyoxypropylene (67) glycol is preferred as the separation inhibitor, diisopropanolamine is preferred as the pH controller, and dibutylhydroxytoluene is preferred as the antioxidant.Type: GrantFiled: March 28, 2012Date of Patent: January 31, 2017Assignees: Maruho Co., Ltd., Mitsubishi Tanabe Pharma CorporationInventors: Tomoki Sakaguchi, Hidetoshi Emi
-
Patent number: 9504650Abstract: A pharmaceutical composition for intranasal administration for human subjects includes vitamin B12 and a pharmaceutically acceptable carrier. The vitamin B12 particles are dispersed in a hydrophobic continuous phase as the pharmaceutically acceptable carrier. The dispersion of solid vitamin B12 particles (crystals or amorphic) in a hydrophobic continuous phase displays very satisfactory bioavailability. Also, the intense red color is reduced significantly, making the pharmaceutical composition acceptable for intranasal use.Type: GrantFiled: November 28, 2013Date of Patent: November 29, 2016Inventor: Klaas Alouis Riepma
-
Patent number: 9427446Abstract: The invention relates to a stable injectable aqueous solution containing diclofenac and thiocolchicoside, or pharmaceutically acceptable salts thereof, and the use thereof in the treatment of painful and inflammatory rheumatic or traumatic conditions of the joints, muscles, tendons and ligaments.Type: GrantFiled: October 21, 2013Date of Patent: August 30, 2016Assignee: EPIFARMA S.R.L.Inventors: Giuseppe Irianni, Cristina Macelloni, Luca Teseschi
-
Patent number: 9381255Abstract: Nanoparticles comprising T3 and their use in treating, e.g., cardiac conditions, for example cardiac arrest, are provided. Such nanoparticles provide improved delivery of T3 and allow for acute treatment and optionally for sustained release of T3 in a patient.Type: GrantFiled: February 26, 2013Date of Patent: July 5, 2016Assignee: AVANT GARDE THERAPEUTICS AND TECHNOLOGIES LLCInventors: Leo Rubin, Shaker Mousa
-
Patent number: 9371297Abstract: The present invention provides novel conformationally-defined macrocyclic compounds that can function as selective modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, central nervous system disorders, bone disorders, genetic disorders, hyperproliferative disorders and inflammatory disorders.Type: GrantFiled: February 8, 2008Date of Patent: June 21, 2016Assignee: Ocera Therapeutics, Inc.Inventors: Hamid Hoveyda, Graeme L. Fraser, Kamel Benakli, Sophie Beauchemin, Martin Brassard, Eric Marsault, Luc Oullet, Mark L. Peterson, Zhigang Wang
-
Patent number: 9364453Abstract: The present disclosure relates to a more effective therapeutic agent capable of improving and treating the axial symptoms (particularly freezing of gait symptom) of patients with Parkinson's disease. Such symptoms in patients with Parkinson's disease can be improved and treated by using L-threo-3,4-dihydroxy-phenylserine (DOPS) and a COMT inhibitor in combination together, optionally with an L-DOPA preparation as well. As a result, the axial symptoms difficult to improve with conventional L-DOPA preparations can be treated, and a therapeutic agent and a treatment method are provided for the axial symptoms of patients with Parkinson's disease, particularly those suffering from the disease at a moderate level or higher.Type: GrantFiled: June 14, 2012Date of Patent: June 14, 2016Assignee: Lundbeck NA Ltd.Inventors: Saburo Sakoda, Kei Fukada
-
Patent number: 9271961Abstract: The invention includes compositions comprising selective AKR1C3 inhibitors. The invention also includes compositions comprising bifunctional AKR1C3 inhibitors and selective androgen receptor modulators. The invention further includes methods of treatment using the compositions of the invention.Type: GrantFiled: October 10, 2013Date of Patent: March 1, 2016Assignee: The Trustees of the University of PennsylvaniaInventors: Trevor M. Penning, Adegoke O. Adeniji, Michael C. Burns, Jeffrey Winkler, Barry Twenter
-
Patent number: 9238016Abstract: The present invention relates to a novel antibiotic, and more specifically relates to an antibiotic composition comprising flufenamic acid as an active ingredient, which can reduce drug toxicity and side effects and the problem of antibiotic resistance caused by excessive use of antibiotics since the composition exhibits a good therapeutic effect, even in a small dose, when it is administered either alone or together with another antibiotic of the prior art.Type: GrantFiled: January 21, 2011Date of Patent: January 19, 2016Assignee: SUNGKYUNKWAN UNIVERSITY FOUNDATION FOR CORPORATE COLLABORATIONInventors: Kyeong Kyu Kim, Sung Wook Kang
-
Patent number: 9180108Abstract: Methods for preparing sterilized baclofen solutions include adjusting the pH to below a desired pH, and steam sterilizing the solution with adjusted pH, which results in the solution having the desired pH. Such solutions may also have low concentrations of 4-CPP. Injectable baclofen solutions having greater than 2 mg/mL baclofen include between 5 mM and 25 mM of a phosphate or sulfate species. The solution has an ionic strength equivalent of about 1.5 M NaCl. The present application also provides baclofen formulations for use in treating spasticity, brain injury, cerebral palsy, spinal cord injury, cervical injury, multiple sclerosis, thoracic injury, or withdrawal symptoms.Type: GrantFiled: October 26, 2012Date of Patent: November 10, 2015Assignee: Medtronic, Inc.Inventors: Michael C. Schmitz, Corinne Dominguez, Thomas E. Keene, Deanna S. Lane, Lanchi T. Le, Jianwei Li, Ngoc T. Lu, Carmen E. Snaza
-
Patent number: 9168238Abstract: A levothyroxine composition includes levothyroxine sodium and mannitol. The composition is a lyophilized solid. The composition may include from 100 to 500 micrograms levothyroxine sodium and from 2 to 4 milligrams mannitol.Type: GrantFiled: March 8, 2015Date of Patent: October 27, 2015Assignee: Fresenius Kabi USA, LLCInventors: John Zhiqiang Jiang, Arunya Usayapant, George Monen
-
Patent number: 9168239Abstract: A levothyroxine composition includes levothyroxine sodium and mannitol. The composition is a lyophilized solid. The composition may include from 100 to 500 micrograms levothyroxine sodium and from 2 to 4 milligrams mannitol.Type: GrantFiled: March 13, 2015Date of Patent: October 27, 2015Assignee: Fresenius Kabi USA, LLCInventors: John Zhiqiang Jiang, Arunya Usayapant, George Monen
-
Patent number: 9101645Abstract: The invention relates generally to treatment of neurological disorders and nervous system injuries. The invention specifically provides methods of using modulators of particular target proteins to modulate degeneration of neurons or portions thereof, such as axons.Type: GrantFiled: October 22, 2009Date of Patent: August 11, 2015Assignee: Genentech, Inc.Inventors: Ryan Watts, Mark Chen, Joseph Wesley Lewcock, Christine Pozniak, Arundhati Sengupta-Ghosh
-
Patent number: 9061968Abstract: Different polymorphs of bromfenac sodium may be prepared and interconverted using crystallization/recrystallization, drying and/or hydration techniques.Type: GrantFiled: September 13, 2013Date of Patent: June 23, 2015Assignee: Johnson Matthey Public Limited CompanyInventors: Saroop Singh Matharu, Gurijala Venu Reddy, James J. Mencel, Xiaoyong Sun
-
Patent number: 9056814Abstract: The present invention relates to the crystalline, polymorphic Form C of the calcimimetic compound {4-[(1R,3S)-3-((R)-1-Naphthalen-1-yl-ethylamino)-cyclopentyl]-phenoxy}-acetic acid, to methods of preparation thereof, to methods of characterization thereof by single crystal X-Ray crystallography (XRC), X-Ray Powder diffractometry, attenuated total reflectance Fourier transform infrared (ATR-FTIR) spectroscopy, Solid State NMR spectroscopy and Differential Scanning Calorimetry (DSC), and to its use.Type: GrantFiled: June 24, 2011Date of Patent: June 16, 2015Assignee: LEO PHARMA A/SInventors: Soren Ebdrup, Kim Troensegaard Nielsen, Tanja Maria Greve
-
Patent number: 9050307Abstract: Levothyroxine, also known as L-thyroxine, synthetic T4, or 3,5,3?,5?-tetraiodo-L-thyronine, CAS number 51-48-9, is a synthetic form of thyroxine, used as a hormone substitute for patients with thyroid conditions. The invention relates to a method for the preparation of an oral levothyroxine composition. The method according to the invention results in liquid levothyroxine formulations that have improved storage stability compared to known liquid levothyroxine formulations.Type: GrantFiled: March 10, 2011Date of Patent: June 9, 2015Assignee: EMP Pharma GmbHInventors: Yannis Psarrakis, Konstantinos I. Lioumis
-
Publication number: 20150148355Abstract: A silicone gel (“silogel”) composition used to deliver pharmaceutical products transdermally as well as a method for producing the silogel composition, which may contain up to 80% additive ingredients. Preferred embodiments of the invention may include silogel compositions which provide high viscosity/no separation due to API. They are not temperature-sensitive, have no shear stress from the ointment mill/EMP, have no gumming up/stickiness, and no hardening.Type: ApplicationFiled: November 24, 2014Publication date: May 28, 2015Inventor: John Olin Trimble
-
Publication number: 20150147385Abstract: Compositions and methods for the treatment of proliferative disorders including proliferative such as breast, uterine cervical, ophthalmic, and pancreatic cancer by the administration of intravenous synthetic curcumin (S-curcumin) are disclosed herein.Type: ApplicationFiled: November 21, 2014Publication date: May 28, 2015Inventor: Lawrence Helson
-
Publication number: 20150147282Abstract: The present invention relates to topical bioadhesive formulations comprising low viscosity, non-liquid crystalline, mixtures of: a) at least one neutral diacyl lipid and/or at least one tocopherol; b) at least one phospholipid; c) at least one biocompatible, oxygen containing, low viscosity organic solvent; wherein at least one bioactive agent is dissolved or dispersed in the low viscosity mixture and wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with an aqueous fluid. The invention additionally relates to a method of delivery of an active agent comprising administration of a preformulation of the invention, a method of treatment comprising administration of a preformulation of the invention and the use of a preformulation of the invention in a method for the manufacture of a medicament.Type: ApplicationFiled: November 24, 2014Publication date: May 28, 2015Inventors: Fredrik JOABSSON, Margareta LINDEN, Krister THURESSON, Fredrik TIBERG
-
Publication number: 20150148420Abstract: Methods for treating insomnia are disclosed. The methods are directed to administering a pharmaceutically effective amount of baclofen to an individual suffering from insomnia. In addition, due to baclofen's positive effects on reducing nighttime reflux events, the present methods are directed to treating insomnia in patients that also suffer from nighttime reflux or gastroesophageal reflux disease (GERD) by administering a pharmaceutically effective amount of baclofen.Type: ApplicationFiled: March 13, 2013Publication date: May 28, 2015Inventor: William C. Orr
-
Publication number: 20150147281Abstract: Provided are methods, test devices, and diagnostic kits for predicting, assessing, and diagnosing the risk of a disease using salivary analysis. The methods comprise providing a whole (unfractionated) saliva sample from a subject; contacting an aliquot of the saliva with two or more lectins under conditions that allow the two or more lectins to bind to a lectin-binding component of the saliva; detecting the amount of bound lectin; and comparing the amount of bound lectin to the amount known to bind a saliva sample from a control patient, to predict the risk of a disease in the subject. Also provided are methods for reducing the risk of a disease and a method for assessing the risk of the disease at a defined level.Type: ApplicationFiled: November 17, 2014Publication date: May 28, 2015Inventors: Patricia A. Denny, Paul C. Denny, Mahvash Navazesh
-
Publication number: 20150148325Abstract: The invention provides extended release pro-liposomal, non-aqueous, pharmaceutical formulations of a hydrophobic active pharmaceutical ingredient (API) of low water solubility but readily dissolved in alcohols and methods for making same. The formulations can be administered by infiltration into an incision, or by injection.Type: ApplicationFiled: May 9, 2013Publication date: May 28, 2015Inventors: Shimon Amselem, Michael Naveh
-
Publication number: 20150147320Abstract: An ophthalmic drug delivery system that contains phospholipid and cholesterol for prolonging drug lifetime in the eyes.Type: ApplicationFiled: December 16, 2014Publication date: May 28, 2015Inventors: SHEUE-FANG SHIH, PO-CHUN CHANG, YUN-LONG TSENG, LUKE S.S. GUO, KEELUNG HONG
-
Patent number: 9040582Abstract: A relaxation formulation structured to induce a deep state of relaxation in a person comprises amounts of tryptophan, melatonin, vitamin B3, and vitamin B6. Another relaxation formulation also includes an amount of tyrosine, and yet another formulation includes an amount of vitamin B12. At least one embodiment of a relaxation formula comprises a physiologically effective amount of gamma-aminobutyric acid (“GABA”). A delivery system is provided to facilitate administration of the relaxation formulation to a person. The delivery system may include an edible high carbohydrate matrix, such as a chocolate brownie. Alternatively, the delivery system may comprise an inert vaporizable compound to allow the components of the relaxation formulation to be inhaled directly into the lungs of a person. Other delivery systems include an aqueous sublingual spray and a beverage.Type: GrantFiled: May 4, 2012Date of Patent: May 26, 2015Inventor: Raymond M. Keller
-
Patent number: 9040577Abstract: Provided herein, in part, is a method of treating a neurological or movement disorder in a patient in need thereof, comprising subcutaneously administering to said patient a pharmaceutically acceptable composition comprising levodopa and optionally carbidopa and optionally entacapone or tolcapone, or pharmaceutically acceptable salts thereof, wherein said composition is administered substantially continuously, and compositions that can be used in the disclosed methods.Type: GrantFiled: April 2, 2014Date of Patent: May 26, 2015Assignee: NeuroDerm, Ltd.Inventors: Oron Yacoby-Zeevi, Mara Nemas
-
Patent number: 9040553Abstract: The present invention provides a process for the synthesis of substituted phenoxymethylpropionic acid and related compounds. The compounds are useful for inhibiting the formation of AGEs (Advanced Glycation End Products).Type: GrantFiled: July 11, 2013Date of Patent: May 26, 2015Assignee: CELL VIABLE CORPORATIONInventors: Iraj Lalezari, Jill Fabricant
-
Patent number: 9040578Abstract: Provided herein, in part, is a method of treating a neurological or movement disorder in a patient in need thereof, comprising subcutaneously administering to said patient a pharmaceutically acceptable composition comprising levodopa and optionally carbidopa and optionally entacapone or tolcapone, or pharmaceutically acceptable salts thereof, wherein said composition is administered substantially continuously, and compositions that can be used in the disclosed methods.Type: GrantFiled: April 2, 2014Date of Patent: May 26, 2015Assignee: NeuroDerm, Ltd.Inventors: Oron Yacoby-Zeevi, Mara Nemas
-
Publication number: 20150141389Abstract: The present disclosure relates to a semi-solid topical drug delivery formulation including a silicone-based excipient, at least one volatile solvent, at least one active configured to be topically delivered through a patient's skin for an intended therapeutic application, and at least one enhancer. The formulation may additionally optionally include at least one agent that provides occlusivity when the formulation is applied onto a patient's skin. The at least one active may be a healthcare and/or pharmaceutical active.Type: ApplicationFiled: March 11, 2013Publication date: May 21, 2015Inventors: Hyder Aliyar, Robert Huber, Gary Loubert, Gerald Schalau
-
Publication number: 20150141515Abstract: The invention relates generally to non-steroidal anti-inflammatory drugs (NSAIDs) and anesthetics, and more particularly, to NSAID and anesthetic compositions, methods of preparing/producing the compositions and methods of delivering, distributing and administering the compositions to patients.Type: ApplicationFiled: November 20, 2014Publication date: May 21, 2015Applicant: FIRSTLINE MEDS, INC.Inventors: JAY A. STOLTENBERG, SHANE HAINES
-
Publication number: 20150133557Abstract: Embodiments of the present invention provide pharmaceutical compositions in unit dosage form that possess a therapeutically effective amount of a levothyroxine sodium; an antioxidant in an amount sufficient to inhibit oxidation of the levothyroxine sodium in the unit dosage form; an amount of a calcium phosphate sufficient to facilitate a processing of the levothyroxine into the unit dosage form, and two or more excipients selected from the group consisting of a filler, a binder, a glidant, a lubricant, a disintegrant, and a surfactant. In such embodiments, the compositions are free of added alditol, added monosaccharide, added disaccharide, and added oligosaccharide and are storage stable.Type: ApplicationFiled: November 14, 2013Publication date: May 14, 2015Inventors: Nilesh Parikh, William Hite
-
Publication number: 20150132380Abstract: Delayed release of a drug to the colon is achieved from a delayed release formulation comprising a core and a coating for the core. The core comprises a drug and the coating comprises an outer layer and at least one layer between the core and the outer layer selected from the group consisting of an isolation layer and an inner layer. The outer layer comprises a mixture of a first polymeric material which is susceptible to attack by colonic bacteria, and a second polymeric material which has a pH threshold at about pH 5 or above. The inner layer comprises a third polymeric material which is soluble in intestinal fluid or gastrointestinal fluid, said third polymeric material being selected from an at least partially neutralised polycarboxylic acid and a non-ionic polymer. In embodiments in which the third polymeric material is a non-ionic polymer, the inner layer comprises at least one of a buffer agent and a base.Type: ApplicationFiled: April 29, 2013Publication date: May 14, 2015Applicant: TILLOTTS PHARMA AGInventors: Roberto Carlos Bravo Gonzalez, Thomas Buser, Frederic Jean-Claude Goutte, Abdul Waseh Basit, Felipe Jose Oliveira Varum, Ana Cristina Freire
-
Publication number: 20150133414Abstract: It was determined whether SNPs in SLC4A5 are associated with salt sensitivity of blood pressure (BP). Subjects consumed an isocaloric constant diet with a randomized order of 7 days low Na+ (10 mmol/d) and 7 days high Na+ (300 mmol/d) intake. Salt sensitivity was defined as a ?7 mm Hg increase in mean arterial pressure (MAP). 35 polymorphisms in 17 candidate genes were assayed. Association analyses with salt sensitivity revealed three variants that associated with salt sensitivity, two in SLC4A5 (rs7571842, rs10177833; P<0.001), and one in GRK4 (rs1801058; P=0.020). Paradoxical changes in blood pressure in response to changes in salt intake were also found associated with a SNP for DRD2 (rs6276). In conclusion, SLC4A5 variants are strongly associated with salt sensitivity of BP in Caucasian and a DRD2 SNP is a marker for paradoxical response to salt intake.Type: ApplicationFiled: April 22, 2013Publication date: May 14, 2015Applicant: University of Virginia Patent FoundationInventors: Robin A. Felder, Robert M. Carey, John E. Jones, Pedro A. Jose, Scott M. Williams
-
Publication number: 20150132396Abstract: The present invention relates to a formulation comprising a pharmaceutically active ingredient and a coating. The invention also relates to the use of the formulation in the treatment and prevention of disorders of the gastrointestinal tract. Also disclosed are methods for preparing the formulations.Type: ApplicationFiled: November 7, 2014Publication date: May 14, 2015Applicant: SIGMOID PHARMA LIMITEDInventors: Ivan Coulter, Vincenzo Aversa, Mónica Rosa, Bernard Francis McDonald
-
Publication number: 20150126606Abstract: The present invention provides a gel formulation comprising diclofenac sodium which has superior transdermal flux properties, which may be used for the topical treatment of pain, such as in osteoarthritis.Type: ApplicationFiled: January 14, 2015Publication date: May 7, 2015Inventors: Ed Kisak, Jagat Singh
-
Publication number: 20150126605Abstract: Disclosed are compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, and one or more excipients, wherein at least one of the excipients modifies release of amantadine. Methods of administering the same are also provided.Type: ApplicationFiled: January 7, 2015Publication date: May 7, 2015Inventors: Gregory T. Went, Timothy J. Fultz
-
Publication number: 20150126607Abstract: The present invention provides a gel formulation comprising diclofenac sodium which has superior transdermal flux properties, which may be used for the topical treatment of pain, such as in osteoarthritis.Type: ApplicationFiled: January 14, 2015Publication date: May 7, 2015Inventors: Ed Kisak, Jagat Singh
-
Publication number: 20150126481Abstract: The present disclosure is drawn to an adhesive peel-forming formulation for dermal delivery of a drug, comprising a drug, a solvent vehicle, and a polymer peel-forming agent. The solvent vehicle can comprise a volatile solvent system comprising one or more volatile solvent, and a non-volatile solvent system comprising two or more non-volatile solvents. The non-volatile solvent system can have a solubility with respect to the drug that is within a window of operable solubility such that the drug is deliverable at therapeutically effective rates over a sustained period of time.Type: ApplicationFiled: November 5, 2014Publication date: May 7, 2015Inventors: Jie Zhang, Kevin S. Warner, Michael A. Ashburn, Larry D. Rigby, Suyi Niu
-
Publication number: 20150126437Abstract: The disclosure provides compounds useful as insect repellents, compositions comprising such repellents, and methods of repelling an arthropod using such compounds and compositions. The disclosure further provides insect traps and method for identifying ligands and cognates for biological molecules.Type: ApplicationFiled: October 17, 2012Publication date: May 7, 2015Applicant: The Regents of the University of CaliforniaInventors: Anandasankar Ray, Sean Michael Boyle
-
Publication number: 20150119465Abstract: Disclosed are compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, and one or more excipients, wherein at least one of the excipients modifies release of amantadine. Methods of administering the same are also provided.Type: ApplicationFiled: January 7, 2015Publication date: April 30, 2015Inventors: Gregory T. Went, Timothy J. Fultz, Timothy S. Burkoth
-
Publication number: 20150119418Abstract: Provided is a pharmaceutical agent containing a compound represented by General Formula (1), a pharmaceutically acceptable salt thereof, or a solvate thereof: wherein A represents a C1-C3 linear alkylene group, in which one methylene group is optionally substituted with O or S; n represents an integer of from 3 to 5; X1 and X2 each independently represent CH or N; W1 and W2 each independently represent a carboxyl group or a tetrazolyl group; V represents a C1-C8 linear or branched alkylene group, in which one methylene group is optionally substituted with O or S; and R represents a substituted phenyl group, for example.Type: ApplicationFiled: April 15, 2013Publication date: April 30, 2015Applicant: TOA EIYO LTD.Inventors: Kazuhiro Uemoto, Yoshimichi Sato, Naoki Okada, Emiko Iimori, Masayuki Kageyama
-
Patent number: 9018259Abstract: The present invention provides a method of treating cancer using benzoic acid derivatives, alone or in combination with standard treatments such as chemotherapy and radiotherapy. Also provided are methods of screening for benzoic derivatives based on their ability to inhibit the enzyme tyrosinase or to bind to and activate PXR/SXR xenobiotic receptors.Type: GrantFiled: May 14, 2012Date of Patent: April 28, 2015Assignee: New York UniversityInventors: Peter C. Brooks, Danielle Morais, Leonard Liebes, Dorothy Rodriguez
-
Publication number: 20150110852Abstract: A system for dermal delivery of lidocaine, bupivacaine, diclofenac, or ketoprofen is provided which comprises at least two components, for example, a sheet of a solid and flexible material, and a vehicle liquid comprising a solvent and optionally other ingredients. A drug, selected from group consisting of lidocaine, bupivacaine, diclofenac, and ketoprofen, can be impregnated in the sheet or contained in the vehicle liquid. These two components can be stored separately and joined either shortly before or at the time of application. To use the system, the vehicle liquid may be applied either on the target skin area or on the sheet, and the sheet may then be applied on the target skin area so that the vehicle liquid is positioned between the sheet and the skin and brought into contact with the ingredients impregnated in the sheet.Type: ApplicationFiled: May 8, 2013Publication date: April 23, 2015Inventor: Jie Zhang
-
Publication number: 20150111937Abstract: The present invention provides methods, compositions, and kits for treating intestinal hyperpermeability in a subject in need thereof, including conditions such as hyperglycemia and underlying diseases such as diabetes, autism, fibromyalgia, inflammatory bowel disease (IBD), graft versus host disease (GVHD), HIV/AIDS, multiple organ dysfunction syndrome, irritable bowel syndrome (IBS), celiac disease, eczema, psoriasis, acute pancreatitis, Parkinson's disease, depression, chronic fatigue syndrome, asthma, multiple sclerosis, arthritis, ankylosing spondylitis, nonalcoholic fatty liver disease, alcoholic cirrhosis, environmental enteropathy, or kwashiorkor.Type: ApplicationFiled: October 21, 2014Publication date: April 23, 2015Inventor: Steven Hoffman
-
Publication number: 20150110883Abstract: The present document describes a composition for sustained, targeted or sustained and targeted delivery of an active ingredient which includes a complex formed between a carboxyl substituted polymer and a lipid. The present document also describes dosage forms containing the composition, and an active ingredient, and methods of using the same for the treatment of diseases.Type: ApplicationFiled: April 30, 2013Publication date: April 23, 2015Inventor: Mircea-Alexandru MATEESCU
-
Publication number: 20150111878Abstract: The present invention provides methods, compositions, and kits for treating intestinal hyperpermeability in a subject in need thereof, including underlying diseases such as diabetes, autism, fibromyalgia, inflammatory bowel disease (IBD), graft versus host disease (GVHD), HIV/AIDS, multiple organ dysfunction syndrome, irritable bowel syndrome (IBS), celiac disease, eczema, psoriasis, acute pancreatitis, Parkinson's disease, depression, chronic fatigue syndrome, asthma, multiple sclerosis, arthritis, ankylosing spondylitis, nonalcoholic fatty liver disease, alcoholic cirrhosis, environmental enteropathy, or kwashiorkor.Type: ApplicationFiled: October 24, 2013Publication date: April 23, 2015Inventor: STEVEN HOFFMAN
-
Publication number: 20150110735Abstract: A centrifugal mixing device can include a shaft assembly that is operably coupled to a motor such that the motor rotates the shaft assembly about a first axis. The devices can further include a turret that is rotatably coupled to the shaft assembly such that the turret rotates about the first axis relative to the shaft assembly. The turret can include a first support, a first canister rotatably coupled to the first support such that the first canister rotates about a second axis, and a second canister rotatably coupled to the first support such that the second canister rotates about a third axis. The turret is configured to rotate about the first axis in a first rotational direction and each of the first and second canisters is configured to rotate about the second and third axes, respectively, in a second rotational direction that is opposite the first rotational direction.Type: ApplicationFiled: October 22, 2013Publication date: April 23, 2015Inventor: Steven Hoffman
-
Publication number: 20150105467Abstract: The present invention is directed to a pharmaceutical composition containing a unit dose of a diclofenac compound effective to induce analgesia; and a beta-cyclodextrin compound; wherein the dose of the diclofenac compound is less than 10 mg. The present invention is also directed to methods of treating a subject in need of analgesia with the pharmaceutical compositions of the invention.Type: ApplicationFiled: December 19, 2014Publication date: April 16, 2015Applicant: JAVELIN PHARMACEUTICALS, INC.Inventors: Curtis Wright, Daniel B. Carr, Fred H. Mermelstein